BIM
TVRD

Bogle Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Bogle Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3,710
Closed -$642K – 460
2016
Q2 		$642K Buy
+3,710
New +$808K 0.04% 304
2015
Q4 		– Sell
-3,959
Closed -$2.04M – 450
2015
Q3 		$2.04M Buy
+3,959
New +$2.65M 0.14% 172

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Bogle Investment Management's TVRD Position: Q3 2016 in Review

Bogle Investment Management sold out of Tvardi Therapeutics (TVRD) in Q3 2016, closing a stake of 3,710 shares — an estimated $642K sold.

Bogle Investment Management first reported a position in TVRD in Q3 2015 and held it in 2 quarters. The position peaked at $2.04M in Q3 2015. 81 funds tracked by Wall St. Rank hold TVRD as of Q3 2016.

  • Bogle Investment Management reported no remaining Tvardi Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Bogle Investment Management sold 3,710 Tvardi Therapeutics shares in Q3 2016, an estimated $642K.
  • Bogle Investment Management first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 2 quarters.
  • Bogle Investment Management's Tvardi Therapeutics position peaked at $2.04M in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2016.

Based on Bogle Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.